Enzalutamide may not affect seizure incidence among men with prostate cancer, seizure risk factors December 7, 2017 Enzalutamide may not increase the incidence of seizure among patients with metastatic castration-resistant prostate cancer (mCRPC) and seizure risk factors, according to a study published in JAMA Oncology.Read more. Source: Cancer Therapy Advisor About Prostate Cancer Prostate Cancer News Risk Factors Treatment Options More for you
Enzalutamide may not increase the incidence of seizure among patients with metastatic castration-resistant prostate cancer (mCRPC) and seizure risk factors, according to a study published in JAMA Oncology.Read more. Source: Cancer Therapy Advisor
Donate Now
